Alpha Tau Medical Ltd WT (DRTSW)

$0.18 +0.02 (11.24%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) -29.16M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 800
Avg Vol 14,994
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 62%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to...

Phone: 972 3 577 4115
Address:
Kiryat HaMada St. 5, Jerusalem, Israel
Latest News on DRTSW
Alpha Tau treats first glioblastoma patient in Israel with Alpha DaRT

2026-06-23T16:01:28.000Z - 11 days ago

Alpha Tau treats first glioblastoma patient in Israel with Alpha DaRT

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Jun 23, 2026, 8:30 AM EDT - 11 days ago

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau gets FDA clearance to complete enrollment in REGAIN trial

2026-06-11T13:17:41.000Z - 23 days ago

Alpha Tau gets FDA clearance to complete enrollment in REGAIN trial

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

Jun 11, 2026, 8:30 AM EDT - 23 days ago

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

Alpha Tau price target raised to $17 from $15 at Barclays

2026-06-04T09:11:16.000Z - 4 weeks ago

Alpha Tau price target raised to $17 from $15 at Barclays

Alpha Tau, Tolmar announce strategic collaboration agreement

2026-06-03T14:53:02.000Z - 4 weeks ago

Alpha Tau, Tolmar announce strategic collaboration agreement

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Jun 3, 2026, 8:30 AM EDT - 4 weeks ago

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Alpha Tau reports positive survival data from pancreatic cancer study

2026-06-01T13:43:39.000Z - 4 weeks ago

Alpha Tau reports positive survival data from pancreatic cancer study

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

Jun 1, 2026, 9:00 AM EDT - 4 weeks ago

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

Alpha Tau Medical Transcript: Lytham Partners Spring 2026 Investor Conference

May 28, 2026, 9:00 AM EDT - 5 weeks ago

Alpha Tau Medical Transcript: Lytham Partners Spring 2026 Investor Conference

Alpha Tau initiated with an Overweight at Barclays

2026-05-28T09:27:08.000Z - 5 weeks ago

Alpha Tau initiated with an Overweight at Barclays

Alpha Tau price target raised to $8 from $5 at Piper Sandler

2026-05-19T11:07:23.000Z - 6 weeks ago

Alpha Tau price target raised to $8 from $5 at Piper Sandler

Alpha Tau reports Q1 EPS (12c), consensus (12c)

2026-05-18T20:08:09.000Z - 6 weeks ago

Alpha Tau reports Q1 EPS (12c), consensus (12c)

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 18, 2026, 4:01 PM EDT - 6 weeks ago

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau Medical Earnings release: Q1 2026

May 18, 2026, 4:00 PM EDT - 6 weeks ago

Alpha Tau Medical Earnings release: Q1 2026

Alpha Tau to Participate in May Investor Conferences

May 18, 2026, 8:30 AM EDT - 6 weeks ago

Alpha Tau to Participate in May Investor Conferences

Alpha Tau Medical Slides: Investor presentation

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Alpha Tau Medical Slides: Investor presentation

Alpha Tau price target raised to $14 from $12 at Ladenburg

2026-05-12T15:35:38.000Z - 7 weeks ago

Alpha Tau price target raised to $14 from $12 at Ladenburg

Alpha Tau price target raised to $15 from $12 at H.C. Wainwright

2026-05-12T10:48:07.000Z - 7 weeks ago

Alpha Tau price target raised to $15 from $12 at H.C. Wainwright

Alpha Tau Medical Transcript: Study result

May 11, 2026, 8:30 AM EDT - 7 weeks ago

Alpha Tau Medical Transcript: Study result

Alpha Tau Medical Press release: Study result

May 11, 2026, 8:30 AM EDT - 7 weeks ago

Alpha Tau Medical Press release: Study result

Alpha Tau Medical Slides: Study result

May 11, 2026, 8:30 AM EDT - 7 weeks ago

Alpha Tau Medical Slides: Study result

Alpha Tau announces interim data from REGAIN trial

2026-05-11T12:24:42.000Z - 7 weeks ago

Alpha Tau announces interim data from REGAIN trial

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

May 11, 2026, 7:00 AM EDT - 7 weeks ago

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

Alpha Tau completes enrollment in ReSTART trial

2026-05-08T15:18:00.000Z - 2 months ago

Alpha Tau completes enrollment in ReSTART trial

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

May 8, 2026, 9:10 AM EDT - 2 months ago

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

May 8, 2026, 9:00 AM EDT - 2 months ago

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

Alpha Tau treats first patient with Alpha DaRT in Italy

2026-05-07T18:29:44.000Z - 2 months ago

Alpha Tau treats first patient with Alpha DaRT in Italy

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas Institute

May 7, 2026, 9:00 AM EDT - 2 months ago

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas Institute

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

May 5, 2026, 9:14 AM EDT - 2 months ago

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

Alpha Tau presents updated results from two clinical trials of Alpha DaRT

2026-05-04T14:13:20.000Z - 2 months ago

Alpha Tau presents updated results from two clinical trials of Alpha DaRT

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

May 4, 2026, 9:17 AM EDT - 2 months ago

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

Medical University of South Carolina and Revival Healthcare Capital Announce Five-Year Strategic Innovation Partnership

Apr 29, 2026, 9:00 AM EDT - 2 months ago

Medical University of South Carolina and Revival Healthcare Capital Announce Five-Year Strategic Innovation Partnership

Alpha Tau Medical Registration statement: Registration filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Alpha Tau Medical Registration statement: Registration filing

Alpha Tau files $300M mixed securities shelf

2026-04-28T10:16:48.000Z - 2 months ago

Alpha Tau files $300M mixed securities shelf

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

Apr 27, 2026, 9:01 AM EDT - 2 months ago

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

Alpha Tau gets FDA investigational device exemption supplement to IMPACT study

2026-04-23T13:33:45.000Z - 2 months ago

Alpha Tau gets FDA investigational device exemption supplement to IMPACT study

Alpha Tau treats first patient in ACAPELLA trial

2026-04-23T13:26:53.000Z - 2 months ago

Alpha Tau treats first patient in ACAPELLA trial

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

Apr 23, 2026, 9:02 AM EDT - 2 months ago

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

Apr 23, 2026, 9:01 AM EDT - 2 months ago

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

Mar 31, 2026, 9:15 AM EDT - 3 months ago

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

Alpha Tau Medical Transcript: Sidoti March Small-Cap Virtual Conference

Mar 18, 2026, 10:00 AM EDT - 3 months ago

Alpha Tau Medical Transcript: Sidoti March Small-Cap Virtual Conference

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Mar 16, 2026, 10:02 AM EDT - 3 months ago

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Alpha Tau price target raised to $9 from $7 at Citi

2026-03-11T09:50:11.000Z - 4 months ago

Alpha Tau price target raised to $9 from $7 at Citi

Alpha Tau Medical Slides: Investor presentation

Mar 10, 2026, 7:00 AM EDT - 4 months ago

Alpha Tau Medical Slides: Investor presentation

Alpha Tau Medical Annual report: Q4 2025

Mar 9, 2026, 5:00 PM EDT - 4 months ago

Alpha Tau Medical Annual report: Q4 2025

Alpha Tau Medical Earnings release: Q4 2025

Mar 9, 2026, 5:00 PM EDT - 4 months ago

Alpha Tau Medical Earnings release: Q4 2025

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Mar 9, 2026, 4:02 PM EDT - 4 months ago

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Alpha Tau Medical Slides: Investor presentation

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Alpha Tau Medical Slides: Investor presentation

HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT

Feb 24, 2026, 8:51 PM EST - 4 months ago

HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

Feb 24, 2026, 9:00 AM EST - 4 months ago

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing

Feb 3, 2026, 12:37 PM EST - 5 months ago

Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Jan 29, 2026, 9:00 AM EST - 5 months ago

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Alpha Tau Medical Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 15, 2026, 4:00 PM EST - 6 months ago

Alpha Tau Medical Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Alpha Tau Medical Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 2:15 PM EST - 6 months ago

Alpha Tau Medical Transcript: 44th Annual J.P. Morgan Healthcare Conference

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Jan 6, 2026, 9:00 AM EST - 6 months ago

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Jan 5, 2026, 9:00 AM EST - 6 months ago

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Alpha Tau Medical Transcript: Sidoti's Year End Virtual Investor Conference

Dec 10, 2025, 11:30 AM EST - 7 months ago

Alpha Tau Medical Transcript: Sidoti's Year End Virtual Investor Conference

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Dec 9, 2025, 9:00 AM EST - 7 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Alpha Tau Medical Slides: Investor presentation

Nov 21, 2025, 7:00 AM EST - 8 months ago

Alpha Tau Medical Slides: Investor presentation

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 20, 2025, 4:05 PM EST - 8 months ago

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Alpha Tau Medical Earnings release: Q3 2025

Nov 20, 2025, 12:00 AM EST - 8 months ago

Alpha Tau Medical Earnings release: Q3 2025

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Nov 11, 2025, 8:30 AM EST - 8 months ago

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Oct 21, 2025, 8:30 AM EDT - 9 months ago

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Oct 17, 2025, 10:04 AM EDT - 9 months ago

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Alpha Tau Medical Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 30, 2025, 12:30 PM EDT - 9 months ago

Alpha Tau Medical Transcript: Lytham Partners Fall 2025 Investor Conference

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Sep 2, 2025, 8:30 AM EDT - 10 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Alpha Tau to Participate in Five September Investor Conferences

Aug 27, 2025, 8:30 AM EDT - 11 months ago

Alpha Tau to Participate in Five September Investor Conferences

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 4:02 PM EDT - 11 months ago

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Alpha Tau Medical Earnings release: Q2 2025

Aug 10, 2025, 6:00 PM EDT - 11 months ago

Alpha Tau Medical Earnings release: Q2 2025

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

Jul 25, 2025, 9:04 AM EDT - 1 year ago

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

Alpha Tau Medical Registration statement: Registration Filing

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Alpha Tau Medical Registration statement: Registration Filing

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 19, 2025, 4:01 PM EDT - 1 year ago

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

Alpha Tau Medical Earnings release: Q1 2025

May 19, 2025, 4:00 PM EDT - 1 year ago

Alpha Tau Medical Earnings release: Q1 2025

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

May 12, 2025, 4:01 PM EDT - 1 year ago

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

ORMP

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

ORMP

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Apr 2, 2025, 8:30 AM EDT - 1 year ago

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Alpha Tau Medical Transcript: Sidoti Small-Cap Virtual Conference

Mar 19, 2025, 11:30 AM EDT - 1 year ago

Alpha Tau Medical Transcript: Sidoti Small-Cap Virtual Conference

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 4:02 PM EDT - 1 year ago

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Alpha Tau Medical Earnings release: Q4 2024

Mar 12, 2025, 4:00 PM EDT - 1 year ago

Alpha Tau Medical Earnings release: Q4 2024

Alpha Tau Medical Annual report: Q4 2024

Mar 12, 2025, 4:00 PM EDT - 1 year ago

Alpha Tau Medical Annual report: Q4 2024

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Feb 24, 2025, 8:30 AM EST - 1 year ago

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Jan 27, 2025, 9:00 AM EST - 1 year ago

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Alpha Tau Medical Transcript: R&D Day 2025

Jan 27, 2025, 8:00 AM EST - 1 year ago

Alpha Tau Medical Transcript: R&D Day 2025

Alpha Tau Medical Slides: FY 2025

Jan 27, 2025, 8:00 AM EST - 1 year ago

Alpha Tau Medical Slides: FY 2025

Alpha Tau Medical Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 16, 2025, 12:45 PM EST - 1 year ago

Alpha Tau Medical Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Dec 18, 2024, 8:30 AM EST - 1 year ago

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Dec 17, 2024, 9:00 AM EST - 1 year ago

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Dec 6, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Alpha Tau Medical Earnings release: Q3 2024

Nov 18, 2024, 6:00 PM EST - 1 year ago

Alpha Tau Medical Earnings release: Q3 2024

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Nov 13, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Sep 20, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC